Express And Clinical Significance Of Nidogen-1 And Nidogen-2 In Ovarian Epithelial Tumors

Objective:To research the expression of the nidogen-2 as a new ovarian serous carcinoma biomarker in serum of patients, and to explore the value of the combination of nidogen-2 and carbohydrateantigenl25 (CA125) in ovarian serous tumor diagnosis. Methods:Nidogen-2 was measured by immunoassay in serum of 40 women with ovarian serous carcinoma.22 women with ovarian serous cystadenoma and 15 ovarian healthy women, meanwhile, monitoring the level of serum CA125 by chemiluminescent immunoassay (CLIA) of patients. Results:1. CA125 concentration in serum of early and advanced ovarian serous carcinoma patients was elevated (P<0.05).And its significantly higher than those of ovarian serous cystadenoma patients and normal (P<0.05); advanced ovarian serous carcinoma was higher than that of early ovarian serous carcinoma ((median,733.20K.U/L;166.80KU/L;P<0.05). However, serum nidogen-2 concentration between normal and varian serous cystadenoma patients was not different. Receive operating characteristic curve(ROC curve) analysis conclude that nidogen-2 could significantly supplement CA125 as an additional ovarian serous carcinoma biomarker.2.Nidogen-2 concentration in serum of early and advanced ovarian serous carcinoma patients was elevated (median.35.57μg/L and 57.23μg/L).and its significantly higher than those of ovarian serous cystadenoma patients and normal (median,15.72μg/L,15.27μg/L; P<0.05); advanced ovarian serous carcinoma was higher than that of early ovarian serous carcinoma (P<0.05). However, serum nidogen-2 concentration between normal and varian serous cystadenoma patients was not different. Receive operating characteristic curve(ROC curve) analysis conclude that nidogen-2 could significantly supplement CA125 as an additional ovarian serous carcinoma biomarker. Conclusion:Nidogen-2 is a new biomarker for ovarian serous carcinoma. Objective To research the expression of the nidogens (nidogen-1 and nidogen-2) in ovarian epithelial tumors, in order to explore the correlation with invasion of the basement membrane in ovarian cancer. Methods Using immunohistochemical method, we examined the nidogen-1 and nidogen-2 expression in 21 malignant epithelial ovarian tissues,11 borderline ovarian tissues and 19 epithelial ovarian benign tissues, and to compare its expression. Results No expression of nidogen-1 and nidogen-2 was found out in ovarian cancer. Nidogen-1 expression rates were 73.68% and 63.64% in epithelial ovarian benign tumors and borderline ovarian tumors, respectively. There were significant differences between three groups (P<0.01). Nidogen-2 expression rates were 68.42% and 54.55% in epithelial ovarian benign tumors and borderline ovarian tumors, respectively. There were significant differences between three groups (P<0.01). Conclusion The expression of nidogen-1 and nidogen-2 correlates closely with invasion of the basement membrane in ovarian cancer.